Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for MS Treatment Investor Brand Network

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body.
The company announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated.
Quantum BioPharma reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS.

Multiple sclerosis remains one of the most challenging neurological diseases facing patients and clinicians because of its progressive nature, unpredictable course and lack of a cure. The disease affects more than 2.8 million people worldwide and approximately 1 million in the USA, and many patients continue to experience worsening disability despite the availability of numerous immune-modulating therapies. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression. Against this backdrop, Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), is advancing Lucid-MS, a patented therapeutic candidate designed to target demyelination and provide neuroprotection in multiple sclerosis to address loss of mobility and function of one’s body.

Multiple sclerosis is a chronic autoimmune and neurodegenerative disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can…